15th Anniversary of Pharmaceutics—Improvement of Drug Bioavailability

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Pharmaceutical Technology, Manufacturing and Devices".

Deadline for manuscript submissions: 20 July 2024 | Viewed by 999

Special Issue Editor


E-Mail Website
Guest Editor
Laboratory for the Conception and Application of Bioactive Molecules, Faculty of Pharmacy, University of Strasbourg, 67400 Illkirch-Graffenstaden, France
Interests: microencapsulation; nanoemulsions; biopharmacy; formulation; pharmaceutical engineering
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Improving the bioavailability of drugs is a critical aspect of pharmaceutical development, as it can lead to better therapeutic outcomes and reduced dosages, thereby minimizing side effects. Bioavailability refers to the proportion of the administered dose of a drug that reaches the systemic circulation and is available to exert its pharmacological effects. This Anniversary Special Issue for the topic “Improvement of bioavailability” will collect some strategies that pharmaceutical researchers and scientists employ to enhance the bioavailability of drugs: formulation optimization, prodrug design, nanotechnology, use of excipients, amorphous solid dispersions, pH adjustment, salt formation, particle size reduction, enhanced permeability, inclusion complexes, co-crystals, modified release formulations, targeted drug delivery.

Due to their inherent and unique physico-chemical characteristics (crystallinity, solubility, stability), each drug, and the appropriate strategy to improve its bioavailability, will depend on its specific characteristics and challenges, such as the administration route. Indeed, pharmaceutical scientists often conduct thorough studies and optimization to select the most effective approach for each particular drug. These strategies will also consider the poor water-soluble characteristics of the drugs to enable adequate bioavailability after administration. This solubility problem greatly hinders pharmaceutical development and ultimately prevents patients from accessing potentially life-saving treatments.

I look forward to receiving your contributions.

Prof. Dr. Thierry Vandamme
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bioavailability
  • in vivo formulation optimization
  • improvement pharmacokinetics
  • biopharmacy
  • decrease side effects
  • poor water solubility
  • oral route
  • parenteral route
  • topical administration
  • preformulation
  • preclinical formulation

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 8366 KiB  
Article
The Development and Characterization of Novel Ionic Liquids Based on Mono- and Dicarboxylates with Meglumine for Drug Solubilizers and Skin Permeation Enhancers
by Takayuki Furuishi, Sara Taguchi, Siran Wang, Kaori Fukuzawa and Etsuo Yonemochi
Pharmaceutics 2024, 16(3), 322; https://doi.org/10.3390/pharmaceutics16030322 - 26 Feb 2024
Viewed by 675
Abstract
In this study, we synthesized a family of novel ionic liquids (ILs) with meglumine (MGM) as cations and tartaric acid (TA), azelaic acid (AA), geranic acid (GA), and capric acid (CPA) as anions, using pharmaceutical additives via simple acid–base neutralization reactions. The successful [...] Read more.
In this study, we synthesized a family of novel ionic liquids (ILs) with meglumine (MGM) as cations and tartaric acid (TA), azelaic acid (AA), geranic acid (GA), and capric acid (CPA) as anions, using pharmaceutical additives via simple acid–base neutralization reactions. The successful synthesis was validated by attenuated total reflection–Fourier transform infrared (ATR-FTIR) and powder X-ray diffraction (PXRD). Thermal analysis using differential scanning calorimetry confirmed the glass transition temperature of MGM-ILs to be within the range of −43.4 °C–−13.8 °C. We investigated the solubilization of 15 drugs with varying pKa and partition coefficient (log P) values using these ILs and performed a comparative analysis. Furthermore, we present MGM-IL as a new skin permeation enhancer for the drug model flurbiprofen (FRP). We confirmed that AA/MGM-IL improves the skin permeation of FRP through hairless mouse skin. Moreover, AA/MGM-IL enhanced drug skin permeability by affecting keratin rather than stratum corneum lipids, as confirmed by ATR-FTIR. To conclude, MGM-ILs exhibited potential as drug solubilizer and skin permeation enhancers of drugs. Full article
Show Figures

Figure 1

Back to TopTop